News articles about T2 Biosystems (NASDAQ:TTOO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. T2 Biosystems earned a news impact score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 45.4859954923996 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media stories that may have impacted Accern’s analysis:
- Don’t Miss This Stock: T2 Biosystems, Inc. (TTOO) (bitcoinpriceupdate.review)
- T2 Biosystems Inc (TTOO) Expected to Announce Earnings of -$0.32 Per Share (americanbankingnews.com)
- T2 Biosystems: Differentiated Infectious Disease Innovator Operating At A Growth Inflection (seekingalpha.com)
- T2 Biosystems Inc (TTOO) Expected to Post Quarterly Sales of $2.86 Million (americanbankingnews.com)
TTOO has been the subject of several analyst reports. ValuEngine raised T2 Biosystems from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 5th. Zacks Investment Research lowered T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Tuesday, April 3rd. Janney Montgomery Scott raised T2 Biosystems from a “neutral” rating to a “buy” rating in a research report on Wednesday, May 9th. Finally, BidaskClub raised T2 Biosystems from a “hold” rating to a “buy” rating in a research report on Thursday, May 24th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $8.05.
T2 Biosystems (NASDAQ:TTOO) last posted its quarterly earnings data on Tuesday, May 8th. The medical equipment provider reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.01. T2 Biosystems had a negative return on equity of 1,117.88% and a negative net margin of 1,003.23%. The firm had revenue of $2.30 million during the quarter, compared to analyst estimates of $1.45 million. The firm’s revenue for the quarter was up 144.7% on a year-over-year basis. analysts forecast that T2 Biosystems will post -1.29 EPS for the current fiscal year.
In other news, Director Stanley Lapidus sold 6,000 shares of T2 Biosystems stock in a transaction dated Tuesday, June 5th. The stock was sold at an average price of $8.87, for a total value of $53,220.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David B. Elsbree acquired 4,225 shares of the stock in a transaction dated Friday, June 1st. The stock was acquired at an average cost of $7.65 per share, with a total value of $32,321.25. The disclosure for this purchase can be found here. Company insiders own 31.50% of the company’s stock.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.